Eli Lilly is the dominant player in incretin obesity and diabetes care. Tirzepatide — Mounjaro for type-2 diabetes, Zepbound for obesity — generated the bulk of 2025 growth, and SURMOUNT-5, the first definitive Phase 3B head-to-head against semaglutide, read out 21.6% mean weight loss at 72 weeks versus semaglutide's 15.4%. Q1 2026 revenue reached $19.8 billion (+56% YoY) on Mounjaro $8.66B (+125%) and Zepbound $4.16B (+80%); Lilly raised 2026 guidance to $82–85B on April 30 and the stock climbed 6.11% on May 1. On May 4, an FAERS hepatic-failure case for Foundayo surfaced, sending shares down 3% premarket before recovering on Lilly's safety-data response and an RBC 'baseline noise' defense.
The next layer determines 2027 and beyond. Orforglipron, marketed as Foundayo, became the first small-molecule oral GLP-1 cleared for obesity in April 2026 and reached roughly 20,000 patients and more than 8,000 prescribers in its first three weeks, though Wegovy pill outpaced it ~20× in early-May IQVIA volume. Retatrutide, the GLP-1/GIP/glucagon triple agonist, posted its first Phase 3 type-2 diabetes readout (TRANSCEND T2D1: A1c down 1.7–2.0 pts, 25–37 lb mean weight loss) on the April 30 call alongside the prior TRIUMPH-4 obesity-with-knee-osteoarthritis data. The retatrutide MASLD Phase 3 (NCT06859268) is enrolling, building on 86% Phase 2 liver-fat reduction. LillyDirect handles self-pay distribution.
The company has spent 2024 and 2025 building peptide CDMO capacity to support both branded volume and the long shadow of the compounding fight. June 2026 forced a manufacturing geography rethink: Lilly halved its planned €2.3 billion ($2.7B) Alzey, Rhineland-Palatinate injectable plant to roughly €1.15 billion and cut planned headcount from 1,000 to 500, citing Germany's proposed 'dynamic manufacturer rebate' and the broader healthcare-reform package. The redirected capital is heading to US sites, most likely Lilly's Pennsylvania facility, alongside the previously announced $4.5 billion Indiana 'Medicine Foundry' R&D and manufacturing project. Boehringer Ingelheim is making a parallel German cut. The Alzey scale-back arrived the same week as STAT News' June 23 disclosure that the FDA and Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, with the White House publicly denying that President Trump applied. Stories here track the pipeline, deals, manufacturing geography, and the share-price moves that follow them.
Eli Lilly shares climbed 6.11% on May 1 as the market digested the company's Q1 2026 print: $19.8B in revenue (+56% YoY), Mounjaro at $8.66B globally (+125%), Zepbound at $4.16B in U.S. sales (+80%), and reported EPS of $8.26 versus the $6.97 consensus. Multiple sell-side analysts revised price targets higher and reiterated or upgraded ratings, citing the strength of the cardiometabolic franchise and the $2 billion guidance raise to $82–85B. The reaction crystallized Lilly's positioning as the GLP-1 leader heading into Novo's May 6 Q1 print.
Fierce Pharma's Oral GLP-1 Tracker reported May 1 that Eli Lilly's Foundayo (orforglipron) reached 5,612 prescriptions in the week ending April 24 — its third full commercial week — up roughly 51% from Week 2's 3,707 scripts but still behind the Wegovy pill's comparable third-week run. RBC and other analysts continue to caution that 8–12 weeks of data are needed to read commercial trajectory through pharmacy-fill noise. On the Q1 earnings call, Lilly USA's Ilya Yuffa said roughly 20,000 patients are now on the drug for obesity or overweight, calling the early launch 'encouraging.'
Profluent, the Bezos-backed AI biotech, announced April 28 a multi-program research collaboration with Eli Lilly worth up to $2.25B in development and commercial milestones plus tiered royalties. Profluent will use its AI platform to design custom recombinases that integrate or modify large stretches of DNA at precise genomic loci, with the goal of generating site-specific gene-editing therapies for diseases of severe unmet need. The deal extends Lilly's diversification beyond peptide therapeutics, following a $1.12B Seamless Therapeutics recombinase deal in January 2026 and the closed Kelonia Therapeutics, Centessa, Orna, and Ajax acquisitions earlier in the quarter.
Eli Lilly reported Q1 2026 worldwide revenue of $19.8 billion, up 56% year over year on 65% volume growth partially offset by a 13% price decline. Mounjaro hit $8.66 billion globally (+125%), Zepbound delivered $4.16 billion in U.S. sales (+80%), and reported Q1 EPS jumped 170% to $8.26. Lilly raised 2026 revenue guidance by $2 billion at each end to $82–85 billion and lifted non-GAAP EPS guidance to $35.50–$37.00. The release also recapped five positive Phase 3 readouts, six new Phase 3 starts, and the closings of the Orna, Centessa, Colonia, and Ajax acquisitions in the quarter.
Eli Lilly's acquisition of Kelonia Therapeutics — announced April 20 with $3.25 billion upfront and up to $7 billion total including milestones — illustrates the company's broader pivot beyond GLP-1 weight-loss drugs. Kelonia develops in vivo CAR-T technology that reprograms patients' T-cells inside the body, eliminating the ex vivo cell-engineering step required by current CAR-T therapies. The deal joins Lilly's recent Centessa Pharmaceuticals (sleep) and Orna Therapeutics (cell therapy) acquisitions as part of a multi-vertical pipeline diversification. Transaction expected to close H2 2026.
Morningstar issued a pre-earnings note ahead of Eli Lilly's April 30 Q1 2026 report raising fair value to $870 from $770 following 2025 results and management guidance. Analysts project 27% top-line growth in 2026 and 20% in 2027, with double-digit growth through end of decade. Mounjaro/Zepbound represented 56% of total sales in 2025, projected to exceed 60% in 2026 with patent protection through 2036. The Q1 print will be the first read on Foundayo launch trajectory after the disappointing 1,390 / 3,707 prescription weeks 1-2.
Two of the largest obesity drug makers report this week: Eli Lilly (April 30) with Foundayo (orforglipron) launch trajectory and Mounjaro/Zepbound dynamics under scrutiny — Lilly previously guided 2026 sales of $80-83 billion (25% growth); and Novo Nordisk (May 6) facing 5-13% guided sales decline as semaglutide loses exclusivity in China, Brazil, Canada, and as the Wegovy pill ramps. Goldman analysts model Lilly's oral GLP-1 capturing 60% of the daily-oral segment by 2030; Novo's projected at 21%. The Foundayo Week 1-2 prescription tracker has shown a slow start.
Hims & Hers announced April 23 a strategic expansion of its U.S. weight loss platform, adding licensed-provider prescriptions for Eli Lilly's Zepbound vials, Zepbound KwikPen, and Foundayo. Prescriptions are fulfilled through LillyDirect pharmacy, completing a dual-supplier arrangement after last month's Novo Nordisk Wegovy collaboration. Shares jumped roughly 7% on the announcement as investors digested the company's pivot from compounded GLP-1s toward branded distribution.
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.
Eli Lilly shares closed down nearly 2% at $918.56 and Novo Nordisk fell ~4% on April 22 after CVS Health's decision to opt out of the Medicare obesity drug coverage pilot triggered CMS to scrap the BALANCE model. The combined market cap loss across the two GLP-1 leaders exceeded $25 billion. Hims & Hers dropped another 6% on continued Amazon One Medical competitive pressure.
Eli Lilly announced positive topline results from ACHIEVE-4, the longest Phase 3 study of Foundayo (orforglipron) to date in 2,700+ adults with type 2 diabetes across 15 countries. The pre-planned analysis showed a 57% lower risk of all-cause death (HR 0.43, p=0.002), while meeting non-inferiority for the prespecified cardiovascular endpoint (HR 0.84). Lilly plans to submit Foundayo for type 2 diabetes to the FDA by end of Q2.
BioSpace analysis frames the ACHIEVE-4 results as a direct answer to the FDA's April 1 letter requesting post-market liver injury and cardiovascular data. The 'outstanding' type 2 diabetes data, combined with cardiovascular safety and all-cause death reductions, strengthens Lilly's position ahead of its Q2 FDA submission and could reduce regulatory friction for the oral GLP-1 franchise.
Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.
The FDA asked Eli Lilly for additional safety data on liver injury linked to Foundayo (orforglipron), plus post-marketing trials to assess cardiovascular event risk and delayed gastric emptying. A lactation study was also required. The letter, signed April 1, was published April 14 — just two weeks after the drug's fast-track approval under the National Priority Voucher program.
UBS analysts forecast 5-6 million Foundayo prescriptions in 2026, projecting roughly $2 billion in launch-year sales. RBC Capital Markets projects peak annual US sales of $36 billion. Eli Lilly pre-stocked $1.5 billion of inventory ahead of the April 6 retail launch.
CNBC reports Eli Lilly's Indian GLP-1 market share fell from 61% to 56% in March as 26 generic semaglutide brands from 13 companies entered the market following patent expiry. Novo Nordisk held steady at 25% after slashing Ozempic prices 38% and Wegovy prices 48%, while Lilly's Mounjaro remains priced 10x above the cheapest generics.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.